Teva Pharmaceutical Industries Limited Discusses Phase Ib Results of Anti-IL-15 Antibody for Vitiligo
Teva Pharmaceutical Industries Limited has shared the results of its Phase Ib trial for the Anti-IL-15 antibody, showing efficacy in treating vitiligo, and plans to move forward to Phase 2b.